Verbesserte Systeme und Verfahren zum Screening auf Schweres Akutes Respiratorisches Syndrom-Coronavirus 2 (sars-Cov-2) von 2019 (covid-19)

Details

Veröffentlichungs-Nr.

EP4614150

Aktenzeichen

EP25162191

Anmeldetag

6. März 2025

Veröffentlichung

10. September 2025

Rechtsraum

EP

IPC

G01N33/569

Abstract

The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.

Anmelder

Firma

Battelle Memorial Institute

Land

🇺🇸 USA

Fachgebiete